Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913835 · ClinicalTrials.gov registry record · Phase 2
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00913835 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 125 participants.
The verdict
NCT00913835, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal Doxorubicin than when treated with Liposomal Doxorubicin alone.
Interventions
- DRUG liposomal doxorubicin
- BIOLOGICAL Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00913835
The ClinicalTrials.gov registry entry for NCT00913835 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which liposomal doxorubicin is the first listed.
NCT00913835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00913835 about?
NCT00913835 is a clinical study titled "A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer". The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal Doxorubicin than when treated with Liposomal Doxorubicin alone.
What is the current status of trial NCT00913835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2009-06. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00913835?
The interventions under investigation include: liposomal doxorubicin (DRUG), Olaratumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00913835?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.